A computed tomography (CT)-derived radiomics approach for predicting primary co-mutations involving TP53 and epidermal growth factor receptor (EGFR) in patients with advanced lung adenocarcinomas (LUAD)

Abstract

CT imaging based artificial intelligence (AI) is expected to distinguish co-mutation status involving <i>TP53</i> and <i>EGFR</i>. The proposed integrated model may serve as an important alternative marker for preselecting patients who will be adaptable to and sensitive to TKIs.